Product Description
Verona Pharma is developing VRP-700 as a treatment for chronic cough. (Sourced from: https://www.veronapharma.com/media/verona-pharma-commences-clinical-trial-vrp700-chronic-cough)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: Eastern America
Company Founding Year: 1668
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Idiopathic Pulmonary Fibrosis|Chronic Cough
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2012-005794-31 |
EPOCh | P2 |
Unknown status |
Chronic Cough|Idiopathic Pulmonary Fibrosis |
2013-08-18 |
2025-06-26 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|